Novavax NVAX Upfront fee amortization — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's upfront fee amortization — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's upfront fee amortization — total revenue?
- Novavax (NVAX) reported upfront fee amortization — total revenue of $12.11M in Q1 2026.
- How has Novavax's upfront fee amortization — total revenue changed year-over-year?
- Novavax's upfront fee amortization — total revenue decreased by 39.2% year-over-year, from $19.91M to $12.11M.
- What does upfront fee amortization — total revenue mean?
- This metric represents the portion of revenue recognized from non-refundable upfront payments received from collaboration or licensing agreements. It reflects the systematic release of deferred revenue as the company fulfills its performance obligations over the term of the contract. Investors use this to gauge the long-term value realization from strategic partnerships and the stability of recurring revenue streams derived from historical licensing deals.